Findings

What do systematic reviews say?

3 questions · 4 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

Targeted immunotherapy alone vs standard targeted therapies

1‐year mortality · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to lower 1‐year mortality compared with standard targeted therapies (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.7 [0.56, 0.87]
1 study · 821 participants
Moderate

Targeted immunotherapy alone vs standard targeted therapies

Quality of life: improved to an important degree · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).

2 findings from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.51 [1.28, 1.78]
1 study · 704 participants
Moderate
Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.37
1 study · 703 participants
Moderate

Targeted immunotherapy alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously treated patients with mRCC

Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.51 [0.4, 0.65]
1 study · 803 participants
Moderate